PMID- 28383653
OWN - NLM
STAT- MEDLINE
DCOM- 20170919
LR  - 20220409
IS  - 1460-2105 (Electronic)
IS  - 0027-8874 (Linking)
VI  - 109
IP  - 10
DP  - 2017 Oct 1
TI  - Immune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape.
LID - 10.1093/jnci/djx034 [doi]
AB  - Current therapies against cancer utilize the patient's immune system for tumor 
      eradication. However, tumor cells can evade immune surveillance of CD8+ T and/or 
      natural killer (NK) cells by various strategies. These include the aberrant 
      expression of human leukocyte antigen (HLA) class I antigens, co-inhibitory or 
      costimulatory molecules, and components of the interferon (IFN) signal 
      transduction pathway. In addition, alterations of the tumor microenvironment 
      could interfere with efficient antitumor immune responses by downregulating or 
      inhibiting the frequency and/or functional activity of immune effector cells and 
      professional antigen-presenting cells. Recently, microRNAs (miRNAs) have been 
      identified as major players in the post-transcriptional regulation of gene 
      expression, thereby controlling many physiological and also pathophysiological 
      processes including neoplastic transformation. Indeed, the cellular miRNA 
      expression pattern is frequently altered in many tumors of distinct origin, 
      demonstrating the tumor suppressive or oncogenic potential of miRNAs. 
      Furthermore, there is increasing evidence that miRNAs could also influence 
      antitumor immune responses by affecting the expression of immune modulatory 
      molecules in tumor and immune cells. Apart from their important role in tumor 
      immune escape and altered tumor-host interaction, immune modulatory miRNAs often 
      exert neoplastic properties, thus representing promising targets for future 
      combined immunotherapy approaches. This review focuses on the characterization of 
      miRNAs involved in the regulation of immune surveillance or immune escape of 
      tumors and their potential use as diagnostic and prognostic biomarkers or as 
      therapeutic targets.
CI  - (c) The Author 2017. Published by Oxford University Press. All rights reserved. For 
      Permissions, please e-mail: journals.permissions@oup.com.
FAU - Eichmuller, Stefan B
AU  - Eichmuller SB
AD  - GMP and T Cell Therapy Unit, German Cancer Research Center (DKFZ), Heidelberg, 
      Germany; Department of Immunology, Faculty of Medicine, The Hebrew University of 
      Jerusalem, Ein Kerem, Jerusalem, Israel; Institute of Medical Immunology, 
      Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany.
FAU - Osen, Wolfram
AU  - Osen W
AD  - GMP and T Cell Therapy Unit, German Cancer Research Center (DKFZ), Heidelberg, 
      Germany; Department of Immunology, Faculty of Medicine, The Hebrew University of 
      Jerusalem, Ein Kerem, Jerusalem, Israel; Institute of Medical Immunology, 
      Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany.
FAU - Mandelboim, Ofer
AU  - Mandelboim O
AD  - GMP and T Cell Therapy Unit, German Cancer Research Center (DKFZ), Heidelberg, 
      Germany; Department of Immunology, Faculty of Medicine, The Hebrew University of 
      Jerusalem, Ein Kerem, Jerusalem, Israel; Institute of Medical Immunology, 
      Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany.
FAU - Seliger, Barbara
AU  - Seliger B
AD  - GMP and T Cell Therapy Unit, German Cancer Research Center (DKFZ), Heidelberg, 
      Germany; Department of Immunology, Faculty of Medicine, The Hebrew University of 
      Jerusalem, Ein Kerem, Jerusalem, Israel; Institute of Medical Immunology, 
      Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - J Natl Cancer Inst
JT  - Journal of the National Cancer Institute
JID - 7503089
RN  - 0 (B7 Antigens)
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-G Antigens)
RN  - 0 (MicroRNAs)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - B7 Antigens/genetics/immunology
MH  - Cancer-Associated Fibroblasts/immunology
MH  - Exosomes
MH  - Gene Expression Regulation, Neoplastic/*immunology
MH  - HLA Antigens/genetics/*immunology
MH  - HLA-G Antigens/genetics/immunology
MH  - Humans
MH  - Immunomodulation/*genetics
MH  - Interferon-gamma/metabolism
MH  - Macrophages/immunology
MH  - MicroRNAs/*genetics
MH  - Neoplasms/*genetics/*immunology
MH  - Signal Transduction/genetics
MH  - T-Lymphocytes/immunology
MH  - Tumor Escape/*genetics/immunology
EDAT- 2017/04/07 06:00
MHDA- 2017/09/20 06:00
CRDT- 2017/04/07 06:00
PHST- 2016/09/15 00:00 [received]
PHST- 2017/02/13 00:00 [accepted]
PHST- 2017/04/07 06:00 [pubmed]
PHST- 2017/09/20 06:00 [medline]
PHST- 2017/04/07 06:00 [entrez]
AID - 3105955 [pii]
AID - 10.1093/jnci/djx034 [doi]
PST - ppublish
SO  - J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx034.